Modulation of Cellular and Viral Gene Expression by the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus

ABSTRACT Kaposi's sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8), is the likely etiological agent of Kaposi's sarcoma and primary effusion lymphoma. Common to these malignancies is that tumor cells are latently infected with KSHV. Viral gene expression is limited to a few genes, one of which is the latency-associated nuclear antigen (LANA), the product of ORF73. Examination of the primary sequence of LANA reveals some structural features reminiscent of transcription factors, leading us to hypothesize that LANA may regulate viral and cellular transcription during latency. In reporter gene-based transient transfection assays, we found that LANA can have either positive or negative effects on gene expression. While expression of a reporter gene from several synthetic promoters was increased in the presence of LANA, expression from the human immunodeficiency virus (HIV) long terminal repeat (LTR)—and from NF-κB-dependent reporter genes—was reduced by LANA expression. In addition, the promoter of KSHV ORF73 itself is activated up to 5.5-fold by LANA. This autoregulation may be important in tumorigenesis, because two other genes (v-cyclin and v-FLIP) with likely roles in cell growth and survival are also controlled by this element. To identify cellular genes influenced by LANA, we employed cDNA array-based expression profiling. Six known genes (and nine expressed sequence tags) were found to be upregulated in LANA-expressing cell lines. One of these, Staf-50, is known to inhibit expression from the HIV LTR; most of the other known genes are interferon inducible, although the interferon genes themselves were not induced by LANA. These data demonstrate that LANA expression has effects on cellular and viral gene expression. We suggest that, whether direct or indirect in origin, these effects may play important roles in the pathobiology of KSHV infection.

[1]  A. Rickinson Epstein-Barr virus. , 2001, Virus research.

[2]  G. Nabel,et al.  p53 inhibition by the LANA protein of KSHV protects against cell death , 1999, Nature.

[3]  T. Schulz,et al.  Latent Nuclear Antigen of Kaposi’s Sarcoma-Associated Herpesvirus Interacts with RING3, a Homolog of theDrosophila Female Sterile Homeotic (fsh) Gene , 1999, Journal of Virology.

[4]  E. Robertson,et al.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. , 1999, Virology.

[5]  C. Rabkin,et al.  Molecular polymorphism of Kaposi's sarcoma-associated herpesvirus (Human herpesvirus 8) latent nuclear antigen: evidence for a large repertoire of viral genotypes and dual infection with different viral genotypes. , 1999, The Journal of infectious diseases.

[6]  P. A. Peterson,et al.  DNA Microarrays of the Complex Human Cytomegalovirus Genome: Profiling Kinetic Class with Drug Sensitivity of Viral Gene Expression , 1999, Journal of Virology.

[7]  F. Christians,et al.  Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1 , 1999, Cell.

[8]  C. Boshoff,et al.  Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. , 1999, Virology.

[9]  M. Ballestas,et al.  Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. , 1999, Science.

[10]  E. van Marck,et al.  Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[12]  A. Haase,et al.  A Cluster of Latently Expressed Genes in Kaposi’s Sarcoma-Associated Herpesvirus , 1998, Journal of Virology.

[13]  D. Ganem,et al.  Limited Transmission of Kaposi’s Sarcoma-Associated Herpesvirus in Cultured Cells , 1998, Journal of Virology.

[14]  G. Kochs,et al.  Mx proteins: mediators of innate resistance to RNA viruses. , 1998, Revue scientifique et technique.

[15]  D. Ganem,et al.  Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. , 1997, The Journal of clinical investigation.

[16]  C. Boshoff,et al.  Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. , 1997, Journal of human virology.

[17]  P. Brown,et al.  Exploring the metabolic and genetic control of gene expression on a genomic scale. , 1997, Science.

[18]  D. Ganem KSHV and Kaposi's Sarcoma: The End of the Beginning? , 1997, Cell.

[19]  L. Rainbow,et al.  The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen , 1997, Journal of virology.

[20]  Yubin Du,et al.  Proviral integrations at the Evi5 locus disrupt a novel 90 kDa protein with homology to the Tre2 oncogene and cell-cycle regulatory proteins , 1997, Oncogene.

[21]  G. Nabel,et al.  Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. , 1997, The New England journal of medicine.

[22]  S. Speck,et al.  Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp) , 1997, Journal of virology.

[23]  J. Russo,et al.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Boshoff,et al.  Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.

[25]  W. Zhong,et al.  The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions , 1996, Journal of virology.

[26]  N. Raab-Traub Pathogenesis of Epstein–Barr virus and its associated malignancies , 1996 .

[27]  E. Operskalski,et al.  The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission , 1996, Nature Medicine.

[28]  J. Phair,et al.  KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma , 1996, Nature Medicine.

[29]  W. Zhong,et al.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Boshoff,et al.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells , 1995, Nature Medicine.

[31]  N. Mechti,et al.  Molecular Cloning of a New Interferon-induced Factor That Represses Human Immunodeficiency Virus Type 1 Long Terminal Repeat Expression (*) , 1995, The Journal of Biological Chemistry.

[32]  D. Baltimore,et al.  Proline-rich sequences that bind to Src homology 3 domains with individual specificities. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Sugden,et al.  An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene , 1995, Journal of virology.

[34]  T. Shenk,et al.  Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Alwine,et al.  Transcriptional activation by the human cytomegalovirus immediate-early proteins: requirements for simple promoter structures and interactions with multiple components of the transcription complex , 1994, Journal of virology.

[36]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[37]  Carlos Lopez,et al.  Human Herpesviruses: List of contributors , 2007 .

[38]  K. Jones,et al.  Tat and the HIV-1 promoter: A model for RNA-mediated regulation of transcription , 1993 .

[39]  P. Pitha,et al.  Transcriptional activation of the tat-defective human immunodeficiency virus type-1 provirus: effect of interferon. , 1992, Virology.

[40]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.

[41]  G. Hayward,et al.  Functional domains of Epstein-Barr virus nuclear antigen EBNA-1 , 1991, Journal of virology.

[42]  B. Sugden,et al.  A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection , 1989, Journal of virology.

[43]  M. Baluda,et al.  Loss of viral receptors in homologous interference by ultraviolet-irradiated Newcastle disease virus. , 1959, Virology.

[44]  D. Botstein,et al.  The transcriptional program in the response of human fibroblasts to serum. , 1999, Science.

[45]  D. Botstein,et al.  Exploring the new world of the genome with DNA microarrays , 1999, Nature Genetics.

[46]  P. Brown,et al.  DNA arrays for analysis of gene expression. , 1999, Methods in enzymology.

[47]  B. Williams,et al.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  K. Struhl,et al.  Yeast transcriptional regulatory mechanisms. , 1995, Annual review of genetics.

[49]  P. Luciw,et al.  Regulatory elements in the long terminal repeat (LTR) of simian foamy virus type 3 (SFV-3). , 1993, Virology.

[50]  M. Ptashne A Genetic Switch , 1986 .

[51]  T. Shenk,et al.  Relief of p 53-mediated transcriptional repression by the adenovirus E 1 B 19-kDa protein or the cellular Bcl-2 protein ( apoptosis / transcriptional regulation ) , 2022 .